<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00902252</url>
  </required_header>
  <id_info>
    <org_study_id>CC-0196-08-A720</org_study_id>
    <nct_id>NCT00902252</nct_id>
  </id_info>
  <brief_title>Multi-National Phase III Vitala™ 12-Hour Wear Test</brief_title>
  <official_title>Multi-National Phase III Vitala™ 12-Hour Wear Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ConvaTec Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ConvaTec Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to demonstrate that the Vitala™ Continence Control
      Device is both safe and effective when worn up to 12 hours per day.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>159 Days</time_frame>
    <description>Will be assessed by measuring the frequency of adverse events relating to the stoma (including gastrointestinal, stomal and surrounding skin events), microbiology profile and stomal vascularity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Restoration of Continence</measure>
    <time_frame>159 days</time_frame>
    <description>Absence of fecal leakage around the device.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>215 Days</time_frame>
    <description>Will be assessed by the following: measurement of health economic outcomes, resource use, security, wear time, comfort, control of odor, control of noise, ease of use during application and removal, subject acceptance of the device.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Colostomy</condition>
  <arm_group>
    <arm_group_label>Usual/Natura®/Vitala™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will wear usual product for 21 days, followed by Natura® for 14 days and followed by Vitala™ for 159 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Usual</intervention_name>
    <description>All subjects will wear their usual pouching system for the first 21 days of the study.</description>
    <arm_group_label>Usual/Natura®/Vitala™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Natura®</intervention_name>
    <description>All subjects will wear the Natura® Flexible Skin Barrier with Flange (Stomahesive® or Durahesive®) in the US and Natura® Stomahesive® Flexible Skin Barrier with Flange in Europe for 14 days.</description>
    <arm_group_label>Usual/Natura®/Vitala™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vitala™</intervention_name>
    <description>After the successful completion of Stages 1 and 2, subjects will enter the &quot;ramp up&quot; schedule to allow the subject to adjust to the device. This consists of weekly increases in wear time of the Vitala™ device beginning with 4 hours of daily wear per week (Days 36 to 42), followed by 6 hours of daily wear time per week (Day 43 to 49), followed by 8 hours of daily wear time (Days 50 to 56) and progressing to 12 hours of daily wear per week (Day 57 to 215).</description>
    <arm_group_label>Usual/Natura®/Vitala™</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is of legal consenting age.

          -  Is able to read, write, and understand the study, the required procedures, and the
             study related documentation.

          -  Has signed the informed consent.

          -  Has an end colostomy of at least 12 weeks duration with formed or semi- formed
             effluent.

          -  Is able to wear a Natura® skin barrier wafer flange in size 45mm or 57 mm.

          -  Is willing to remove and replace the skin barrier wafer after three days, more often
             if desired.

          -  Has a stoma that protrudes no more than 2 cm at rest.

          -  Has demonstrated success in wearing a traditional pouching system. (Investigator
             judgment)

          -  Is willing to participate in the trial for a total of 215 days. (approximately 7
             months)

          -  Is willing to meet with the investigator for a total of 12 scheduled visits plus
             additional visits as deemed necessary by the investigator.

          -  Has the ability to do complete self-care.

        Exclusion Criteria:

          -  Has known skin sensitivity to any component of the products being tested.

          -  Has a skin rating of &quot;2&quot; or greater according to the Skin Rating Scale.

          -  Is receiving radiation in the area of the pouching system.

          -  Is receiving chemotherapy other than a stable regimen of maintenance chemotherapy.

          -  Requires a pouch belt while wearing Vitala

          -  Requires convexity or a moldable skin barrier.

          -  Has participated in a clinical study within the past 90 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dheerendra Kommala, MD</last_name>
    <role>Study Director</role>
    <affiliation>ConvaTec Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Tuscon</city>
        <state>Arizona</state>
        <zip>85742</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ET Nursing Services</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington County Hospital</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Restored Images</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Image Specialties</name>
      <address>
        <city>St. Joseph</city>
        <state>Missouri</state>
        <zip>64506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colon and Rectal Surgery</name>
      <address>
        <city>Reynoldsburg</city>
        <state>Ohio</state>
        <zip>43068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Triwalk</city>
        <zip>23966</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Homerton University Hospital NHS</name>
      <address>
        <city>London</city>
        <zip>E9 6SR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelsea and Westminster Hospital</name>
      <address>
        <city>London</city>
        <zip>SW10 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2009</study_first_submitted>
  <study_first_submitted_qc>May 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2009</study_first_posted>
  <last_update_submitted>May 14, 2010</last_update_submitted>
  <last_update_submitted_qc>May 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dheerendra Kommala, MD / VP of Clinical Development</name_title>
    <organization>Convatec</organization>
  </responsible_party>
  <pending_results>
    <submitted>February 6, 2014</submitted>
    <returned>March 27, 2014</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

